ST2 biomarker

ST2 – is the latest biological marker used to assess the risk of heart failure and other cardiological and vascular diseases. Its significance is increasingly recognized in clinical practice as it is an independent prognostic indicator associated with myocardial hypertrophy and fibrosis processes. ST2 enables more accurate identification of patients at risk for acute or chronic heart failure, even when clinical symptoms are not yet expressed.

ST2 concentration in the blood reflects heart wall tension, inflammatory processes, and macrophage activation. The advantage is that the value of this marker does not depend on comorbidities such as renal failure, anemia, or arterial hypertension, nor is it influenced by a patient's age, gender, or body weight. This makes ST2 a highly reliable and universal marker among various patient groups.

ST2 testing allows earlier identification of patients at risk of poor cardiovascular disease prognosis, thereby improving their survival. This is particularly important for patients with heart failure, as ST2 concentration can provide insight into disease progression and help optimize treatment intensity or medication dosages.

Test principle: ST2 concentration is determined by an immunochemical method from a venous blood sample. Results are presented in ng/ml units. The average normal concentration is considered to be around 18 ng/ml, with a significant risk threshold of 35 ng/ml.

Recommendations:

• Recommended for patients suspected of acute or chronic heart failure.
• Useful for monitoring heart diseases and individualizing treatment plans.
• Assigned to assess the risk of heart fibrosis and inflammation.
• Helps select patients even before clinical symptoms manifest.
• Test results can be used to decide on treatment intensity or drug dosing.
• No specific preparation is required for the test.